Incretin Atlas › Trials › FLOW
FLOW
Semaglutide · CKD + T2D, T2D + CKD
Design
- Molecule(s)
- Semaglutide
- Population
- CKD + T2D, T2D + CKD
- Official title
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2019-06 → 2024-01
- Participants
- 3533
- Duration
- 178 weeks
- Registry
- NCT03819153
Cardiovascular and kidney outcomes
FLOW semaglutide 1.0 mg vs placebo · T2D + CKD · n = 3533 · 2024 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE Major cardiovascular events: nonfatal MI, nonfatal stroke, or CV death (confirmatory secondary outcome, time to first event) | 0.82 | 0.68–0.98 | 212 vs 254 | verified |
| Cardiovascular death Death from cardiovascular causes (includes undetermined causes adjudicated by the committee) | 0.71 | 0.56–0.89 | 123 vs 169 | verified |
| All-cause death Death from any cause (confirmatory secondary outcome) | 0.80 | 0.67–0.95 | 227 vs 279 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (fatal MI not separately reported) | 0.80 | 0.55–1.15 | 52 vs 64 | verified |
| Stroke Nonfatal stroke only (fatal stroke not separately reported) | 1.22 | 0.84–1.77 | 63 vs 51 | verified |
| Major kidney disease events primary Major kidney disease events: kidney failure (long-term dialysis, transplantation, or sustained eGFR <15), sustained ≥50% eGFR reduction from baseline, or death | 0.76 | 0.66–0.88 | 331 vs 410 | verified |
| Sustained eGFR decline (≥50 %) Persistent >=50% reduction from baseline in eGFR (component of primary outcome; persistent = two consecutive measurements >=4 weeks apart) | 0.73 | 0.59–0.89 | 165 vs 213 | verified |
| Kidney failure (eGFR <15) Persistent eGFR <15 ml/min/1.73 m2 (component of primary outcome) | 0.80 | 0.61–1.06 | 92 vs 110 | verified |
| Kidney failure (kidney-replacement therapy) Initiation of kidney-replacement therapy (dialysis or transplantation; component of primary outcome) | 0.84 | 0.63–1.12 | 87 vs 100 | verified |
| Major adverse limb events Major adverse limb event, time-to-first-event analysis | 0.56 | 0.30–1.02 | 16 vs 28 | verified |
Verbatim quotes (10)
- 3-point MACE · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1E
The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.029)
- Cardiovascular death · Table 2; Figure 1C
Death from cardiovascular causes 123 (7.0) 169 (9.6) 0.71 (0.56 to 0.89)
- All-cause death · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1F
The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs. 279 events; hazard ratio, 0.80; 95% CI, 0.67 to 0.95, P = 0.01)
- Myocardial infarction · Table 2
Nonfatal myocardial infarction 52 (2.9) 64 (3.6) 0.80 (0.55 to 1.15)
- Stroke · Table 2
Nonfatal stroke 63 (3.6) 51 (2.9) 1.22 (0.84 to 1.77)
- Major kidney disease events · Results, Primary Outcome; Table 2; Figure 1A
331 first events [5.8 per 100 patient-years of follow-up] vs. 410 first events [7.5 per 100 patient-years]), ... hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003
- Sustained eGFR decline (≥50 %) · Table 2, components of primary outcome
Persistent ≥50% reduction from baseline in eGFR 165 (9.3) 213 (12.1) 0.73 (0.59 to 0.89)
- Kidney failure (eGFR <15) · Table 2, components of primary outcome
Persistent eGFR <15 ml/min/1.73 m2 92 (5.2) 110 (6.2) 0.80 (0.61 to 1.06)
- Kidney failure (kidney-replacement therapy) · Table 2, components of primary outcome
Initiation of kidney-replacement therapy 87 (4.9) 100 (5.7) 0.84 (0.63 to 1.12)
- Major adverse limb events · Table 2 (continued), lower section
Major adverse limb event in a time-to-first-event analysis — no. of events 16 28 0.56 (0.30 to 1.02)
Outcomes in the indication
FLOW Semaglutide · CKD + T2D · 178 weeks · n = 3533 seed
Major kidney events HR 0.76; all-cause death HR 0.80
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death) week 177 | +331.0 | +410.0 | +0.8 (+0.7 to +0.9) hazard ratio | verified |
Verbatim quotes (1)
- Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003)
Primary sources
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PMID: 38785209.
- Novo Nordisk A/S. Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW). ClinicalTrials.gov identifier NCT03819153. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03819153
How to cite this page
Medical Adviser's Group. Incretin Atlas: FLOW. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/flow/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.